AstraZeneca touts a fresh cut of Farxiga data targeting diabetes patients with chronic kidney disease
As the SGLT2 race for diabetes turns hot, AstraZeneca — one of the earliest players in the field — has laid out data demonstrating its drug’s benefits for a subset of type 2 diabetics.
Farxiga (dapagliflozin) was compared against a placebo among type 2 diabetes patients with a moderate stage of chronic kidney disease in a Phase III study dubbed Derive. The 321-patient study met its primary endpoint of changing hemoglobin A1C (HbA1C) and all three of its secondary endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.